Company Overview: Inovio


Industry News

24 May

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of...

Read more

10 May

Inovio Pharmaceuticals Reports 2017 First Quarter Financial Results

PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today reported financial results for the quarter ended March 31, 2017. Total revenue was $10.4 million for the three months ended March 31, 2017, compared to $8.1 million for the same period in 2016. Total operating...

Read more

10 May

Inovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer

PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer T cell responses targeting HPV-associated tumors, and...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address